Aviv Scientific Raises $40 Million in Series B Funding to Create the World’s First High Dimensional OMICS Database of the Aging Process

·3-min read

Expansion of Global Network of Medical Clinics Initiates a New Era in Aging and Brain Health

TEL AVIV, September 22, 2021--(BUSINESS WIRE)--Today world leader in research and clinical treatment of age-related cognitive and functional decline to maximize human performance, Aviv Scientific, announces the closing of $40 million in a oversubscribed Series B funding round. Led by Israel’s largest public medical services conglomerate, Danel LTD; Jeff Horing’s Deep Insight Fund; the country’s most successful high-tech angels and entrepreneurs; international longevity and healthspan optimization focused investors; the Series B fundraise will accelerate the global rollout of its network of medical clinics and the development of the Aviv Aging Database. For the first time, in depth comprehensive OMICS data detailing the aging process in healthy adults will be captured, expediting the development of therapeutics and approaches to notably extend healthspan, and ultimately lifespan, in humans.

Based on an exclusive partnership with the world’s largest hyperbaric medicine and research facility, the Sagol Center at Shamir Medical Center in Israel, the Aviv Medical Program was developed over the past decade, combining unique protocols of Hyperbaric Oxygen Therapy (HBOT) with a proprietary personalized program of cognitive and physical training. More than 1,000 people worldwide have already been treated according to Aviv’s progressive twelve-week program, currently offered in Florida and Dubai at Aviv Clinics.

Composed of longitudinal and comprehensive phenotype and genotype of normal and pathological adults, Aviv is currently developing an in-depth high dimensional OMICS database. Information, including neuro-cognitive, physiologic, biomarkers and genetic evaluations is collected using designated comprehensive assessments at specific timepoints along with continuous monitoring through wearables and home-based applications. By obtaining a one-of-a-kind multi-OMICS tagged database with clinical information, Aviv will be able to draw useful insights of aging, management, pharmacogenomics and preventive medicine to ultimately underpin and promote the development of healthspan extension therapeutics.

"Aviv is playing a starring role in today’s healthy aging movement," states Jonathan Preminger, Co-Founder and Chief Executive Officer of Aviv Scientific. "The new round of funding is a testament to our outstanding clinical outcomes, world-class team, strategic partnerships and cutting-edge technology. We look forward to seeing sustained success and are inspired by the strong support from investors who share our vision."

The financing follows several recent accomplishments involving the completion of pivotal study in late 2020 as seen in Insider, Bloomberg, New York Post, The CEO Magazine, Popular Mechanics and Popular Science. The application marked the first-time scientists successfully managed to biologically reverse the aging process in healthy humans, using hyperbaric oxygen therapy to lengthen telomeres and reduce senescent cells while also demonstrating cognitive enhancement in healthy adults.

Aviv intends to use the Series B funding to rapidly expand its global clinic footprint in the United States, Europe and Asia; grow its in-depth high dimensional OMICS database; bolster its technology and accelerate its medical research program.

About Aviv Scientific

Aviv Scientific is a leader in age-related cognitive and functional decline and novel applications of hyperbaric oxygen therapy (HBOT) to maximize human performance. Based on an exclusive partnership with the world’s largest hyperbaric medicine research facility, the Sagol Center at Shamir Medical Center in Israel, Aviv Scientific is introducing a global network of clinics delivering a highly effective personalized treatment – The Aviv Medical Program. The three-month regimen designed to improve the aging process in healthy adults, was developed on over a decade of research and development under the scientific leadership of Shai Efrati, M.D., Chair of Aviv Scientific’s Medical Advisory Board and Director of the Sagol Center.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005272/en/

Contacts

Victoria Hathaway
401-575-9640
victoria.hathaway@finnpartners.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting